BiomimX Applications - Advanced Therapies
Predict the toxicity and efficacy of innovative gene, antibody and cell therapeutics in human models of physiology and pathology.
The Challenge
Predicting human responses to innovative therapeutics is still challenging due to their inherited and human-specific complexity in the mode of action.
Innovative and advanced products such as gene, antibody-drug conjugate (ADC) and cell therapeutics need complex human-based in vitro system to fully predict their clinical outcome. Gene therapies are specifically designed to target human genes and required efficient delivery systems that need to be tested not only for efficiency, but also for safety. Similarly, ADC and cell therapies specifically target human cells, expressing peculiar markers and thus need human-based in vitro models. Animal models indeed poorly recapitulate human physiology and pathology, thus making ineffective the translation of results.
BiomimX's Solution
Building complex human models to fully assess the safety and efficacy of advanced products before clinical trials.
The versatility of BiomimX’s uBeat® powered solutions allows you to build ad hoc human models able to elucidate the mechanism of action of advanced therapeutics. The capabilities to get data from model encompassing single or multiple tissues allows for a better assessment of products safety and efficacy, already in the pre-clinical phase. Our technology can bridge the gap left by simplistic in vitro and animal models, improving the efficacy of your R&D pipeline relying on human-based data.
Gene, ADC and Cell therapy toxicity
Assess advance therapeutics’ toxicity in human-relevant in vitro models.
Cardiotoxicity studies are performed in uHeart, a 3D functional model of the human physiological myocardium, spontaneously and synchronously beating.
Hepatotoxicity studies are performed in uHep, a liver sinusoid-on-chip system which may account for vasculariziation and with high viability and functionality.
Intestinal toxicity studies are performed in uGut, a 3D model of the gastrointestinal tract with functional epithelial and endothelial barriers.
Consult with our experts to explore the best solutions for assessing the safety of your advance therapeutics.
Gene, ADC and Cell therapy efficacy
Assess advance therapeutics’ efficacy and mode of action inside human-relevant in vitro models, developed in ad hoc uBeat® Platform.
Take advantage from our fully established pathological models such as uScar and uKnee to assess the efficacy and mode of action of your advanced therapeutics in specific field of applications such as cardiac fibrosis and OA-related pathologies.
Consult with our experts to explore the already tested solutions or to build an ad hoc study to reply to specific questions.
Take Advantage from our uBeat® based solution
- Rely on toxicity and efficacy data of your advanced therapeutics generated in human relevant models of your choice.
- Elucidate the mechanism of action of your advanced therapeutics during discovery or development to generate data that is more readily transferable to clinical settings.